id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0926-0009,FDA,FDA-2022-E-0926,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-29T05:00:00Z,2025,1,2025-01-29T05:00:00Z,,2025-01-29T13:17:22Z,,0,0,09000064868facba
FDA-2022-E-0926-0006,FDA,FDA-2022-E-0926,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-17T05:00:00Z,2024,1,2024-01-17T05:00:00Z,,2024-01-17T19:06:44Z,,0,0,090000648638a027
FDA-2022-E-0926-0005,FDA,FDA-2022-E-0926,Determination of Regulatory Review Period for Purposes of Patent Extension; CYTALUX,Notice,Determinations,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,2024-06-25T03:59:59Z,2024-06-15T01:00:26Z,2023-28507,0,0,090000648635c493
FDA-2022-E-0926-0004,FDA,FDA-2022-E-0926,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T19:50:01Z,,0,0,09000064862d409a
FDA-2022-E-0926-0003,FDA,FDA-2022-E-0926,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-21T04:00:00Z,2022,9,2022-09-21T04:00:00Z,,2022-09-22T12:11:07Z,,0,0,090000648534649e
FDA-2022-E-0926-0001,FDA,FDA-2022-E-0926,Patent Term Extension Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-05-27T04:00:00Z,2022,5,2022-05-27T04:00:00Z,,2022-05-27T15:32:07Z,,0,0,09000064850fd0f9
FDA-2022-E-0926-0002,FDA,FDA-2022-E-0926,"Patent Extension Application from McAndrews, Held, & Malloy, Ltd. (on behalf of Purdue Research Foundation)",Other,Application,2022-05-27T04:00:00Z,2022,5,2022-05-27T04:00:00Z,,2022-05-27T15:32:13Z,,0,0,09000064850fe0cf